FIG 5.

Treatment with type I IFN or IL-27 boosts CD4mc sensitization of HIV-1-infected cells to ADCC. Primary CD4⁺ T cells infected with the transmitted/founder virus CH58 (CH58 T/F), either treated for 24 h with type I IFN (IFN-α and IFN-β) or IL-27 or not treated, were used as target cells, and autologous PBMCs were used as effector cells in our FACS-based ADCC assay. Shown are the percentages of ADCC-mediated killing obtained with sera from 10 HIV-1-infected individuals in the presence of the CD4mc BNM-III-170 (50 μM) or an equivalent volume of DMSO. Values are means ± standard error of the means (SEM) (error bars). Statistical significance was tested using a paired t test or Wilcoxon matched-pair signed-rank test based on statistical normality (*, P < 0.05; **, P < 0.01, ***, P < 0.001; ****, P < 0.0001; ns, nonsignificant).